FDA Commissioner Makary Resigns After White House Moved to Fire Him

What Happens Next

• →The acting commissioner, drawn from the food safety division, deprioritizes pharmaceutical and device oversight in favor of food regulatory continuity, delaying pending drug approvals and enforcement actions during the transition period.
• →E-cigarette and tobacco companies accelerate regulatory submissions and lobbying efforts during the leadership vacuum, anticipating a more permissive FDA posture on flavored nicotine products aligned with the White House's demonstrated preference.
• →FDA staff attrition accelerates as career scientists and reviewers - already demoralized by mass layoffs - interpret Makary's ouster as confirmation that scientific independence is subordinate to political directives, degrading the agency's institutional capacity for complex reviews.

Near-term: Pending drug and device approvals face 2-4 month delays as the acting commissioner conducts internal policy reviews and reassigns leadership roles vacated during Makary's tenure. Long-term: Sustained politicization of FDA leadership drives pharmaceutical and medtech companies to shift clinical trial and approval strategies toward the EMA and other foreign regulators, eroding the FDA's primacy as the global gold-standard regulatory body.